Merck KGaA (0O14 – Research Report) received a Buy rating and a €205.00 price target from Goldman Sachs analyst James Quigley today. The ...

Merck, a leading science and technology company, and Siemens deepened their cooperation aimed at taking smart manufacturing ...

An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative breast cancer (TNBC). Now, the PD-1 inhibitor has gold-standard overall ...

Affecting as many as 9 million people across the globe, cancer cachexia is a life-threatening condition ... first approval for the given indication. Merck (MRK) has been one of the stocks most ...

DelveInsight's CEACAM5 Drugs Market Insights report includes a comprehensive understanding of current treatment practices, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of the lymph nodes. The development of novel targeted therapies and ...